These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17950494)

  • 1. Structure of a novel thrombin inhibitor with an uncharged D-amino acid as P1 residue.
    Friedrich R; Riester D; Göttig P; Thürk M; Schwienhorst A; Bode W
    Eur J Med Chem; 2008 Jun; 43(6):1330-5. PubMed ID: 17950494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
    Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
    Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New bivalent thrombin inhibitors with N(alpha)(methyl)arginine at the P1-position.
    Steinmetzer T; Batdordshjin M; Pineda F; Seyfarth L; Vogel A; Reissmann S; Hauptmann J; Stürzebecher J
    Biol Chem; 2000 Jul; 381(7):603-10. PubMed ID: 10987367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of peptide bonds to inhibitor-protease binding: crystal structures of the turkey ovomucoid third domain backbone variants OMTKY3-Pro18I and OMTKY3-psi[COO]-Leu18I in complex with Streptomyces griseus proteinase B (SGPB) and the structure of the free inhibitor, OMTKY-3-psi[CH2NH2+]-Asp19I.
    Bateman KS; Huang K; Anderson S; Lu W; Qasim MA; Laskowski M; James MN
    J Mol Biol; 2001 Jan; 305(4):839-49. PubMed ID: 11162096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
    De Simone G; Lombardi A; Galdiero S; Nastri F; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
    Protein Sci; 1998 Feb; 7(2):243-53. PubMed ID: 9521099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The crystal structure of alpha-thrombin-hirunorm IV complex reveals a novel specificity site recognition mode.
    Lombardi A; De Simone G; Nastri F; Galdiero S; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
    Protein Sci; 1999 Jan; 8(1):91-5. PubMed ID: 10210187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety.
    Mack H; Baucke D; Hornberger W; Lange UE; Seitz W; Höffken HW
    Bioorg Med Chem Lett; 2006 May; 16(10):2641-7. PubMed ID: 16517159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors.
    Winquist J; Geschwindner S; Xue Y; Gustavsson L; Musil D; Deinum J; Danielson UH
    Biochemistry; 2013 Jan; 52(4):613-26. PubMed ID: 23290007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and SAR of thrombin inhibitors incorporating a novel 4-amino-morpholinone sscaffold: analysis of X-ray crystal structure of enzyme inhibitor complex.
    Nilsson JW; Kvarnström I; Musil D; Nilsson I; Samulesson B
    J Med Chem; 2003 Sep; 46(19):3985-4001. PubMed ID: 12954052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
    Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structures of thrombin complexed to a novel series of synthetic inhibitors containing a 5,5-trans-lactone template.
    Jhoti H; Cleasby A; Reid S; Thomas PJ; Weir M; Wonacott A
    Biochemistry; 1999 Jun; 38(25):7969-77. PubMed ID: 10387040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. {4(S)-(Piperidin-1-ylcarbonyl)-4-[3-(trifluoromethyl)phenylsulfonamido]butyl}guanidinium chloride: a model of a graftable thrombin inhibitor.
    Michaux C; Salvagnini C; Norberg B; Marchand-Brynaert J; Wouters J
    Acta Crystallogr C; 2006 Dec; 62(Pt 12):o691-3. PubMed ID: 17148914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The determination of protonation states in proteins.
    Ahmed HU; Blakeley MP; Cianci M; Cruickshank DW; Hubbard JA; Helliwell JR
    Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):906-22. PubMed ID: 17642517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.
    Nantermet PG; Burgey CS; Robinson KA; Pellicore JM; Newton CL; Deng JZ; Selnick HG; Lewis SD; Lucas BJ; Krueger JA; Miller-Stein C; White RB; Wong B; McMasters DR; Wallace AA; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP; Lyle TA
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2771-5. PubMed ID: 15911253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies.
    De Simone G; Menchise V; Omaggio S; Pedone C; Scozzafava A; Supuran CT
    Biochemistry; 2003 Aug; 42(30):9013-21. PubMed ID: 12885234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.
    Deng JZ; McMasters DR; Rabbat PM; Williams PD; Coburn CA; Yan Y; Kuo LC; Lewis SD; Lucas BJ; Krueger JA; Strulovici B; Vacca JP; Lyle TA; Burgey CS
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4411-6. PubMed ID: 16137886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compounds binding to the S2-S3 pockets of thrombin.
    Nilsson M; Hämäläinen M; Ivarsson M; Gottfries J; Xue Y; Hansson S; Isaksson R; Fex T
    J Med Chem; 2009 May; 52(9):2708-15. PubMed ID: 19371038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis.
    Lumma WC; Witherup KM; Tucker TJ; Brady SF; Sisko JT; Naylor-Olsen AM; Lewis SD; Lucas BJ; Vacca JP
    J Med Chem; 1998 Mar; 41(7):1011-3. PubMed ID: 9544200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.